Emmaus Q2 2026 net income $1.3M vs $1.1M loss; revenue up 124% on NIT license

Emmaus Life Sciences, Inc.

2026-Q2 EPS reported -$0.03 revenue$8,300,000

Net revenues $6.3M for Q2 2026 vs $2.8M in Q2 2025, driven by NIT license revenue recognition.
Operating expenses fell to $2.1M from $3.0M; income from operations $3.8M vs $0.4M loss.
Net income $1.3M ($0.02 EPS) vs net loss $1.1M (-$0.02 EPS); cash $2.8M at June 30, 2026.
NIT exclusive license for Endari in US/Canada effective May 15, 2026; upfront payment and royalties recognized.
Weighted-average shares 70.2M vs 63.9M in prior-year quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.